Article

Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.

Department of Immunology, Genentech, South San Francisco, CA 94080, USA.
Blood (Impact Factor: 10.43). 01/2008; 110(12):3959-67. DOI: 10.1182/blood-2007-04-088088
Source: PubMed

ABSTRACT Removal of pathogenic B lymphocytes by depletion of monoclonal antibodies (mAbs) or deprivation of B-cell survival factors has demonstrated clinical benefit in both oncologic and immunologic diseases. Partial clinical responses and emerging data demonstrating incomplete B-cell depletion after immunotherapy fuels the need for improved therapeutic modalities. Lessons from the first generation of therapeutics directed against B-cell-specific antigens (CD20, CD22) are being applied to develop novel antibodies with additional functional attributes. We describe the generation of a novel class of B-cell-directed therapy (anti-BR3 mAbs) that combines the depleting capacity of a therapeutic mAb and blockade of B-cell-activating factor (BAFF)-BR3 B-cell survival. In mice, treatment with antagonistic anti-BR3 antibodies results in quantitatively greater reduction in some B-cell subsets and qualitatively different effects on bone marrow plasma cells compared with BR3-Fc BAFF blockade or with anti-CD20 treatment. Comparative analysis of BR3-Fc and anti-BR3 mAb reveals a lower B-cell dependence for BAFF-mediated survival in nonhuman primates than in mice. This novel class of B-cell-targeted therapies shows species characteristics in mice and primates that will guide translation to treatment of human disease.

Download full-text

Full-text

Available from: Suhasini Iyer, Mar 31, 2014
0 Followers
 · 
169 Views
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: The TNF family ligands BAFF/BLyS and APRIL play important roles in the homeostasis and function of B cells. BAFF binds to the receptors BAFF-R/BR3, BCMA, and TACI, whereas APRIL interacts with BCMA, TACI, and sulfated side chains of proteoglycans. BAFF and APRIL are initially synthesized as membrane-bound proteins that can be released into soluble forms by proteolytic processing. Both cytokines display the characteristic homotrimeric structure of the TNF family, but BAFF is further able to oligomerize under certain conditions into a virus-like particle containing 20 trimers. All three receptors for BAFF are smaller than canonical TNF receptors and form compact but extensive interactions with the ligands. Similarities and differences in these interactions account for the observed binding specificities to BAFF and APRIL. In contrast to TACI and BCMA, proteoglycans interact with APRIL at distinct sites and may serve to concentrate APRIL at defined anatomical locations. Multimeric forms of BAFF and APRIL are required for signaling through TACI, whereas BAFF-R responds to all forms of BAFF, suggesting that many different types of BAFF and APRIL may be functionally relevant to control distinct aspects of their biology. KeywordsStructure-B cells-Oligomerization-Antibody-Survival-Receptor-Ligand-TNF
    01/1970: pages 1-18;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoid neoplasms usually display various genetic alterations that dysregulate normal immune functions, primarily through abnormal cellular growth and survival mechanisms that expand and immortalize a single neoplastic clone, to the detriment of the indigenous normal immune system, and eventually the host. In addition to the nonrandom genetic translocations, other important cellular abnormalities are also involved. The abnormalities in cellular regulation generally occur in one or more of the following four areas: cell death, cell cycle progression, NF-κB activation, or critical signal transduction pathways, usually from cell surface growth and survival receptors. Recent studies of BLyS/BAFF family members, BLyS and APRIL, have shown their importance in non-Hodgkin’s B-cell lymphoma (NHL-B), chronic lymphoid leukemia (CLL), and plasma cell myeloma cell growth and survival. In this chapter, we will discuss how BLyS is involved in mechanisms of tumor cell proliferation and survival in these malignant lymphoid cells. Potential therapeutic approaches to these lymphoid malignances through inhibition of BLyS signaling pathways are also discussed. KeywordsBLyS-BAFF-NHL-B-LBCL-MCL-NF-κB-NF-AT
    01/1970: pages 245-263;
Show more